SCHEMBL4674596

SCHEMBL4674596

COc1ccc(Cc2nc(CC(=O)C(=O)c3nc[nH]n3)cs2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2C9 P11712 3/20 0.47
CYP2C19 P33261 3/20 0.47
GAA P10253 1/20 0.47
ALOX12 P18054 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 2/20 0.44
NPC1 O15118 1/20 0.44
KDM4E B2RXH2 3/20 0.44
HPGD P15428 2/20 0.44
RECQL P46063 1/20 0.44
CYP2D6 P10635 1/20 0.43
HTT P42858 1/20 0.43
HDAC1 Q13547 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899379 0.92 HDAC1 (0.43) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4671892 0.89 BCHE (0.37) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4677685 0.88 KMT2A (0.37) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4674614 0.87 HDAC1 (0.39) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4674383 0.87 LMNA (0.40) LMNAGAAMAPTSMN1; SMN2ALDH1A1
SCHEMBL4676248 0.87 HDAC1 (0.47) LMNAGAAMAPTSMN1; SMN2ALDH1A1
SCHEMBL4671667 0.86 HDAC1 (0.37) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4674866 0.84 LMNA (0.46) LMNACYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4671165 0.81 BCHE (0.39) POLBALDH1A1KMT2AMEN1RAB9A
SCHEMBL4674077 0.80 SAE1 (0.36) LMNACYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 LMNA 659/4885CYP1A2 61/4885CYP3A4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.